Schlich Ltd +44(0) 1903 717001 info@schlich.co.uk
  • Schlich China
  • Client Portal
Schlich Ltd
  • Our Firm
  • IP Services
    • Patents
    • EPO Oppositions & Appeals
    • UKIPO Proceedings
    • UPC Proceedings
    • Trade Marks
    • Designs
    • IP Strategy
  • Patent Specialities
    • Life Sciences & Biotech
    • Chemical & Pharmaceutical
    • Mechanical, Engineering and Physics
    • Software, Electronics and Communications
  • Insights
  • Inventors’ Zone
  • Contact
Select Page
Food for fork: stretchy cheese and contradictory post-filed evidence

Food for fork: stretchy cheese and contradictory post-filed evidence

by Sean Hughes | Jul 11, 2024 | EPO

Vegan Cheese Product Claim T 0629/22 concerned European patent no. 3422865 (subject-matter: vegan cheese and preparation thereof). The product claim was distinguished from the prior art according to the type and amount of starch used in the vegan cheese. However, the...
Therapeutic Effect – a Higher Bar for Novelty than for Sufficiency at the EPO

Therapeutic Effect – a Higher Bar for Novelty than for Sufficiency at the EPO

by David Eyre | Jul 8, 2024 | EPO

These provisions for “second medical use” also rely on the claims for use in a method of treatment being interpreted to include the physiological or technical effect of the treatment as being a functional feature of the claim.   However, the interpretation...
Clarity Once Again: The EPO’s Enlarged Board of Appeal Suggests the Current Test for Whether to Admit Post-Filed Evidence into Proceedings Should Stand

Clarity Once Again: The EPO’s Enlarged Board of Appeal Suggests the Current Test for Whether to Admit Post-Filed Evidence into Proceedings Should Stand

by Sean Hutchinson | Jun 12, 2024 | EPO

Background In our article of January 2024, we reported that the opponent in the case underpinning the “plausibility” referral (G 2/21) had filed a petition for review of the referring board’s decision (T 116/18) by the Enlarged Board of Appeal. That petition is...
Back in the Maze: Is the Decision of the Referring Board in G 2/21 About to be Overturned?

Back in the Maze: Is the Decision of the Referring Board in G 2/21 About to be Overturned?

by Sean Hutchinson | Jan 25, 2024 | EPO

When the EPO’s Enlarged Board of Appeal issued its decision in G 2/21 (the “plausibility” referral), many were left wondering what the requirements were for a patent applicant/proprietor to be able to rely on post-filed evidence in support of inventive step. However,...
Generic Drug Manufacturers Protected by the “Skinny Label” provisions of the Hatch–Waxman Act

Generic Drug Manufacturers Protected by the “Skinny Label” provisions of the Hatch–Waxman Act

by David Eyre | Jan 22, 2024 | US & International

Background – Skinny Labelling Enacted by the Hatch–Waxman Act  In 1984, the US Congress introduced a law called the Drug Price Competition and Patent Term Restoration Act, or the “Hatch–Waxman” Act after the two sponsors of the bill: Representative Henry Waxman and...
« Older Entries
Next Entries »

Recent Posts

  • By Touatis! “Obelix®” Has A Reputation
  • Schlich recognised in IAM Patent 1000 rankings for 2026
  • First UPC Referral to the CJEU: Just How Long is the Long-Arm Jurisdiction of the UPC?
  • Sequence Identity Claims After T 0137/24: How Broad Is Too Broad?
  • Schlich’s 2026 Reception Aboard the Golden Hinde

Recent Comments

    CIPA
    IPReg
    CITMA
    • Instagram

    Services

    • Patents
    • EPO Oppositions & Appeals
    • UKIPO Proceedings
    • UPC Proceedings
    • Trade Marks
    • Designs
    • IP Strategy

    About

    • Our Firm
    • Careers
    • Our People
    • Policies

    Contact

    • Contact
    • Inventors Zone
    © 2026 Schlich, All rights reserved | Built by Molokini
    European Patent and Trade Mark Attorneys. Schlich Ltd is a UK limited company, registration no. 05238489, address: 9 St Catherine's Road, Littlehampton, West Sussex, BN17 5HS.